{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tolbutamide", "query": { "intervention": "Tolbutamide" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 12, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tolbutamide&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-02T05:37:50.091Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03291288", "title": "Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Drug Interaction Potential" ], "interventions": [ { "name": "Tolbutamide", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" }, { "name": "Pexidartinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2018-02-26", "completion_date": "2021-04-16", "has_results": true, "last_update_posted_date": "2021-05-14", "last_synced_at": "2026-09-02T05:37:50.091Z", "location_count": 8, "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Palo Alto, California + 5 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Palo Alto", "state": "California" }, { "city": "Westwood", "state": "Kansas" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03291288" }, { "nct_id": "NCT03457597", "title": "Study in Healthy Subjects to Determine the Effect of Relacorilant on Exposure to Probe Substrates for Cytochrome P450s", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Midazolam hydrochloride", "type": "DRUG" }, { "name": "Metoprolol tartrate", "type": "DRUG" }, { "name": "Pioglitazone hydrochloride", "type": "DRUG" }, { "name": "Tolbutamide", "type": "DRUG" }, { "name": "Omeprazole", "type": "DRUG" }, { "name": "Relacorilant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Corcept Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 27, "start_date": "2018-03-06", "completion_date": "2018-04-28", "has_results": false, "last_update_posted_date": "2018-05-17", "last_synced_at": "2026-09-02T05:37:50.091Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03457597" }, { "nct_id": "NCT01068860", "title": "To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Type 2 Diabetes Mellitus", "Impaired Glucose Tolerance" ], "interventions": [ { "name": "Canakinumab 150 mg", "type": "DRUG" }, { "name": "Placebo to Canakinumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "74 Years", "sex": "ALL", "summary": "18 Years to 74 Years" }, "enrollment_count": 246, "start_date": "2010-02", "completion_date": "2010-08", "has_results": true, "last_update_posted_date": "2011-09-05", "last_synced_at": "2026-09-02T05:37:50.091Z", "location_count": 11, "location_summary": "Los Angeles, California • Santa Ana, California • Spring Valley, California + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Santa Ana", "state": "California" }, { "city": "Spring Valley", "state": "California" }, { "city": "Madisonville", "state": "Kentucky" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01068860" }, { "nct_id": "NCT01218620", "title": "Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Solid Neoplasm" ], "interventions": [ { "name": "Gamma-Secretase Inhibitor RO4929097", "type": "DRUG" }, { "name": "Ketoconazole", "type": "DRUG" }, { "name": "Rifampin", "type": "DRUG" }, { "name": "Midazolam Hydrochloride", "type": "DRUG" }, { "name": "Omeprazole", "type": "DRUG" }, { "name": "Tolbutamide", "type": "DRUG" }, { "name": "Dextromethorphan Hydrobromide", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2010-09", "completion_date": "2014-12", "has_results": false, "last_update_posted_date": "2014-12-23", "last_synced_at": "2026-09-02T05:37:50.091Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01218620" }, { "nct_id": "NCT05097716", "title": "Study to Evaluate the Effect of Multiple-Dose Ritlecitinib on the Pharmacokinetics (PK) of Tolbutamide", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Ritlecitinib", "type": "DRUG" }, { "name": "Tolbutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 12, "start_date": "2021-11-02", "completion_date": "2022-01-10", "has_results": true, "last_update_posted_date": "2023-10-06", "last_synced_at": "2026-09-02T05:37:50.091Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT05097716" }, { "nct_id": "NCT01061112", "title": "Effects of Genotype on CYP2C9 Drug Interactions", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Healthy" ], "interventions": [ { "name": "Flurbiprofen Control - Flurbiprofen Only", "type": "DRUG" }, { "name": "Flurbiprofen Inhibition - Flurbiprofen & Fluconazole", "type": "DRUG" }, { "name": "Ketoprofen Control - Ketoprofen Only", "type": "DRUG" }, { "name": "Ketoprofen Inhibition - Ketoprofen & Fluconazole", "type": "DRUG" }, { "name": "Tolbutamide Control - Tolbutamide Only", "type": "DRUG" }, { "name": "Tolbutamide Inhibition - Tolbutamide & Fluconazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 23, "start_date": "2009-12", "completion_date": "2014-06", "has_results": false, "last_update_posted_date": "2019-07-18", "last_synced_at": "2026-09-02T05:37:50.091Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01061112" }, { "nct_id": "NCT01525628", "title": "Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "midazolam", "type": "DRUG" }, { "name": "BI 201335", "type": "DRUG" }, { "name": "tenofovir", "type": "DRUG" }, { "name": "caffeine", "type": "DRUG" }, { "name": "tolbutamide", "type": "DRUG" }, { "name": "pegylated interferon", "type": "DRUG" }, { "name": "BI 207127", "type": "DRUG" }, { "name": "ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 72, "start_date": "2012-04", "completion_date": "2014-10", "has_results": true, "last_update_posted_date": "2016-06-10", "last_synced_at": "2026-09-02T05:37:50.091Z", "location_count": 5, "location_summary": "La Mesa, California • Rockville, Maryland • Marlton, New Jersey + 2 more", "locations": [ { "city": "La Mesa", "state": "California" }, { "city": "Rockville", "state": "Maryland" }, { "city": "Marlton", "state": "New Jersey" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT01525628" }, { "nct_id": "NCT00741468", "title": "Open-Label, Multiple-Dose, Non-Randomized Study to Assess Drug-Drug Interactions of Proellex® in Female Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Drug Interactions" ], "interventions": [ { "name": "Proellex", "type": "DRUG" }, { "name": "CYP1A2 probe", "type": "DRUG" }, { "name": "CYP2C9 probe", "type": "DRUG" }, { "name": "CYP2C19 probe", "type": "DRUG" }, { "name": "CYP2D6 probe", "type": "DRUG" }, { "name": "CYP3A4 probe", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Repros Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "48 Years", "sex": "FEMALE", "summary": "18 Years to 48 Years · Female only" }, "enrollment_count": 18, "start_date": "2008-07", "completion_date": "2008-10", "has_results": true, "last_update_posted_date": "2014-08-22", "last_synced_at": "2026-09-02T05:37:50.091Z", "location_count": 1, "location_summary": "Hackensack, New Jersey", "locations": [ { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00741468" }, { "nct_id": "NCT03716427", "title": "Drug Interaction Study of CT1812 in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "CT1812", "type": "DRUG" }, { "name": "tolbutamide", "type": "DRUG" }, { "name": "dextromethorphan", "type": "DRUG" }, { "name": "Omeprazole", "type": "DRUG" }, { "name": "midazolam", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cognition Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 16, "start_date": "2016-11-10", "completion_date": "2017-02-15", "has_results": false, "last_update_posted_date": "2018-10-23", "last_synced_at": "2026-09-02T05:37:50.091Z", "location_count": 1, "location_summary": "Kalamazoo, Michigan", "locations": [ { "city": "Kalamazoo", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03716427" }, { "nct_id": "NCT03492580", "title": "A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Diabetes Mellitus, Type 2", "Cardiovascular Diseases" ], "interventions": [ { "name": "Canagliflozin", "type": "DRUG" }, { "name": "Empagliflozin", "type": "DRUG" }, { "name": "Dapagliflozin", "type": "DRUG" }, { "name": "Dipeptidyl Peptidase-4 (DPP-4) Inhibitors", "type": "DRUG" }, { "name": "Glucagon-like Peptide-1 (GLP-1) Agonist", "type": "DRUG" }, { "name": "Anti-hyperglycemic Agents (AHA)", "type": "DRUG" }, { "name": "Thiazolidinediones (TZD)", "type": "DRUG" }, { "name": "Sulfonylureas (SU)", "type": "DRUG" }, { "name": "Insulin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 714582, "start_date": "2018-02-22", "completion_date": "2018-06-25", "has_results": false, "last_update_posted_date": "2025-06-25", "last_synced_at": "2026-09-02T05:37:50.091Z", "location_count": 1, "location_summary": "Titusville, New Jersey", "locations": [ { "city": "Titusville", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03492580" } ] }